Search
for
Sort by
Research 30 of 1000+
- Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study
- Baseline Neutrophil-to-Lymphocyte Ratio Stratifies Early Trichoscopic Response to Platelet-Rich Plasma–Based Regimens in Non-Scarring Alopecia: A Real-World Cohort with Internal Validation Using an Interpretable Neural Network
- Baseline hair loss severity as a potential confounder in studies on minoxidil and low-level laser therapy
- Baseline trichoscopic values for afro‐textured hair in indigenous South Africans show lower density and unique features
- Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
- Impact of baseline PSA level on quality of life measures of general health and sexual satisfaction/drive in men with BPH treated with finasteride or placebo
- 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
- 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
- 50392 Impact of Baseline Psychiatric and Autoimmune Comorbidities on Economic Burden for Patients in the United States in the First Year After Diagnosis with Alopecia Areata
- 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
- BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
- Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
- 75122 Real-world Effectiveness of Baricitinib for Severe Alopecia Areata by Baseline Hair Loss and Episode Duration: Results from a Prospective Observational Study
- Prepared hair oil from Arnica montana- Q in castor and mustard base oil in definite proportion with standardization
- Maintenance of optimised hair growth from viable terminal scalp hair follicles at baseline with oral finasteride in male pattern hair loss and first evidence of a “drug dependency” and a post-finasteride “rebound effect”.
- 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
- Contact allergy to essential oils cannot always be predicted from allergy to fragrance markers in the baseline series
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study
- Investigative guidelines for alopecia areata
- Results of 60-second timed hair counts in women between the ages of 20–60 years
- Prognosis of early-onset alopecia areata: An evidence-based case report
- Clinical Insights and Prognostic Factors in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Cohort Study
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
- Trichoscopic Analysis of Healthy Indian Males for Standardization of the Measurable Parameters: An Observational, Cross-sectional Study
- The use of diphencyprone in dermatology: A retospective audit
- A study of normal eyelashes in Japanese individuals
- 104 Flibanserin Subset Analyses and the Androgenics of Hypoactive Sexual Desire Disorder
- CSF 5-HIAA as a predictor of treatment response in trichotillomania.
- Circulating monocytes as a marker of response to adalimumab in patients with hidradenitis suppurativa